» Articles » PMID: 10886148

Post-kala-azar Dermal Leishmaniasis in the Sudan: Clinical Presentation and Differential Diagnosis

Overview
Journal Br J Dermatol
Specialty Dermatology
Date 2000 Jul 25
PMID 10886148
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Post-kala-azar dermal leishmaniasis (PKDL) is a common complication following kala-azar (visceral leishmaniasis). In a prospective study in a village in the endemic area for kala-azar in the Sudan, 105 of 183 (57%) kala-azar patients developed PKDL. There was a significantly higher PKDL rate (69%) in those who received inadequate and irregular treatment of kala-azar than in those who were treated with stibogluconate 20 mg kg-1 daily for 15 days (35%). The group of patients who developed PKDL did not differ from those who did not develop PKDL with regard to age and sex distribution, reduction in spleen size, and conversion in the leishmanin skin test (LST). In a clinical study, 416 PKDL patients were analysed and divided according to grade of severity. Severe PKDL was more frequent in younger age groups (P < 0.001); there was an inverse correlation between grade and conversion in the LST (P < 0.01). In 16% of patients tested, parasites were demonstrated in inguinal lymph node or bone marrow aspirates, indicating still visceral disease (para-kala-azar dermal leishmaniasis); there was no correlation between the presence of parasites and grade of severity. Conversion rates in the LST were lower than in those who did not have demonstrable parasites (11% and 37%, respectively; P < 0.01). In the absence of reliable and practical diagnostic tests, PKDL may be diagnosed on clinical grounds and differentiated from other conditions, of which miliaria rubra was the most common. Differentiation from leprosy was most difficult.

Citing Articles

Role of neutrophils in the pathogenesis of Post Kala-azar Dermal Leishmaniasis (PKDL).

Roy M, Sengupta R, Chakraborty B, Chatterjee U, von Stebut E, Kaye P PLoS Negl Trop Dis. 2024; 18(11):e0012655.

PMID: 39602398 PMC: 11602034. DOI: 10.1371/journal.pntd.0012655.


Differences in the Cellular Immune Response during and after Treatment of Sudanese Patients with Post-kala-azar Dermal Leishmaniasis, and Possible Implications for Outcome.

Torres A, Younis B, Alamin M, Tesema S, Bernardo L, Solana J J Epidemiol Glob Health. 2024; 14(3):1167-1179.

PMID: 39007942 PMC: 11442715. DOI: 10.1007/s44197-024-00270-0.


Visceral leishmaniasis follow-up and treatment outcomes in Tiaty East and West sub-counties, Kenya: Cure, relapse, and Post Kala-azar Dermal Leishmaniasis.

Kennedy G, OBrien K, Nyakundi H, Kitondo M, Biwott W, Wamai R PLoS One. 2024; 19(6):e0306067.

PMID: 38917127 PMC: 11198830. DOI: 10.1371/journal.pone.0306067.


A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery.

Hasan M, Proma S, Hossain M, Arifuzzaman M, Islam N, Siddique M BMC Infect Dis. 2023; 23(1):885.

PMID: 38110894 PMC: 10729440. DOI: 10.1186/s12879-023-08918-1.


Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.

Younis B, Musa A, Monnerat S, Abdelrahim Saeed M, Awad Gasim Khalil E, Elbashir Ahmed A PLoS Negl Trop Dis. 2023; 17(11):e0011780.

PMID: 37988402 PMC: 10721181. DOI: 10.1371/journal.pntd.0011780.